This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

John F. Warren, MD; Anthony J. Aldave, MD; M. Srinivasan, MD; Eugene J. Thonar, PhD; Abha B. Kumar, MD; Vicky Cevallos, BS; John P. Whitcher, MD, MPH; Todd P. Margolis, MD, PhD

Arch Ophthalmol. 2003;121:1608-1612.

Objective  To further characterize the role of the carbohydrate sulfotransferase (CHST6) gene in macular corneal dystrophy (MCD) through identification of causative mutations in a cohort of affected patients from southern India.

Methods  Genomic DNA was extracted from buccal epithelium of 75 patients (51 families) with MCD, 33 unaffected relatives, and 48 healthy volunteers. The coding region of the CHST6 gene was evaluated by means of polymerase chain reaction amplification and direct sequencing. Subtyping of MCD into types I and II was performed by measuring serum levels of antigenic keratan sulfate.

Results  Seventy patients were classified as having type I MCD, and 5 patients as having type II MCD. Analysis of the CHST6 coding region in patients with type I MCD identified 11 homozygous missense mutations (Leu22Arg, His42Tyr, Arg50Cys, Arg50Leu, Ser53Leu, Arg97Pro, Cys102Tyr, Arg127Cys, Arg205Gln, His249Pro, and Glu274Lys), 2 compound heterozygous missense mutations (Arg93His and Ala206Thr), 5 homozygous deletion mutations (delCG707-708, delC890, delA1237, del1748-1770, and delORF), and 2 homozygous replacement mutations (ACCTAC 1273 GGT, and GCG 1304 AT). One patient with type II MCD was heterozygous for the C890 deletion mutation, whereas 4 possessed no CHST6 coding region mutations.

Conclusion  A variety of previously unreported mutations in the coding region of the CHST6 gene are associated with type I MCD in a cohort of patients in southern India.

Clinical Relevance  An improved understanding of the genetic basis of MCD allows for earlier, more accurate diagnosis of affected individuals, and may provide the foundation for the development of novel disease treatments.

From the Francis I. Proctor Foundation and the Department of Ophthalmology, University of California–San Francisco (Drs Warren, Aldave, Kumar, Whitcher, and Margolis and Ms Cevallos); the Cornea and External Disease Service, Aravind Eye Hospital, Madurai, India (Dr Srinivasan); and the Departments of Biochemistry, Orthopedic Surgery, and Internal Medicine, Rush Medical College, Chicago, Ill (Dr Thonar). Dr Aldave is now with the Jules Stein Eye Institute, University of California–Los Angeles. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sequencing of the CHST6 gene in Czech macular corneal dystrophy patients supports the evidence of a founder mutation
Liskova et al.
Br J Ophthalmol 2008;92:265-267.
ABSTRACT | FULL TEXT  

Elucidating the Molecular Genetic Basis of the Corneal Dystrophies: Are We There Yet?
Aldave and Sonmez
Arch Ophthalmol 2007;125:177-186.
ABSTRACT | FULL TEXT  

Matrix morphogenesis in cornea is mediated by the modification of keratan sulfate by GlcNAc 6-O-sulfotransferase
Hayashida et al.
Proc. Natl. Acad. Sci. USA 2006;103:13333-13338.
ABSTRACT | FULL TEXT